Table 1.
Patient characteristics | |
Median age at enrollment (range) | 10 years (2–21 years) |
Male | 14 (63.6 %) |
Female | 8 (36.4 %) |
Histology | |
Ependymoma | 9 (40.9 %) |
Anaplastic ependymoma | 13 (59.1 %) |
Location of primary ependymoma | |
Supratentorial | 11 (50 %) |
Infratentorial | 11 (50 %) |
Location of recurrence | |
Locala | 19 (86 %) |
Distant (outside of radiation field) | 3 (13 %) |
Prior therapy | |
Chemotherapy | 18 (82 %) |
One systemic therapy | 13 |
Two systemic therapies | 3 |
Three systemic therapies | 2 |
Radiotherapy | 22 (100 %) |
Surgery | 22 (100 %) |
Courses of lapatinib and bevacizumab | |
Median (range) | 2 (1–14) |
Response | |
Objective responses (CR + PR) | 0 |
n cases stable disease for >4 months | 4 |
n cases progressive disease | 16 |
Median time to progression | 7.9 weeks |
Four patients had evidence of metastatic disease upon enrollment as baseline disease evaluation and the disease was within the prior radiation field.